Compare PNTG & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | ANAB |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.3B |
| IPO Year | 2019 | 2015 |
| Metric | PNTG | ANAB |
|---|---|---|
| Price | $34.36 | $63.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $36.83 | ★ $68.10 |
| AVG Volume (30 Days) | 288.6K | ★ 477.1K |
| Earning Date | 05-27-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 91.02 |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $947,705,000.00 | $234,603,000.00 |
| Revenue This Year | $24.93 | N/A |
| Revenue Next Year | $7.52 | $43.04 |
| P/E Ratio | $40.51 | ★ N/A |
| Revenue Growth | 36.31 | ★ 157.01 |
| 52 Week Low | $21.74 | $15.32 |
| 52 Week High | $35.25 | $66.66 |
| Indicator | PNTG | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 63.83 |
| Support Level | $27.34 | $43.67 |
| Resistance Level | $35.00 | N/A |
| Average True Range (ATR) | 1.68 | 3.68 |
| MACD | 0.04 | 0.66 |
| Stochastic Oscillator | 82.68 | 73.68 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).